FOGSI General Clinical Practice Recommendations

Management of Iron Deficiency Anemia in Pregnancy

Chairperson
Dr. Alka Kriplani
MD, FRCOG, FAMS, FICOG, FIMSA, FICMCH, FCLS
Professor & Head, Dept. of Obst-Gynae
Director In-charge WHO-CCR, HRRC & Family Planning
All India Institute of Medical Sciences, New Delhi, India

Coordinators
Dr. Aparna Sharma
MD, DNB, MNAMS
Assistant Professor, Obstetrics and Gynaecology
All India Institute of Medical Sciences
New Delhi

Dr. A G Radhika
DGO, DNB, MNAMS
Senior Specialist
University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi

Experts
Dr Zoya Ali Rizvi
MBBS (Gold Medalist), MPH (London UK).
Assistant Commissioner - Adolescent Health, MOHFW, Govt of India, New Delhi

Dr. K. Madhavan Nair
PhD, FAMS, FNAAS, FTAS
MSc (Biochemistry)
Scientist ‘F’ & Head, Micronutrient Research Group, National Institute of Nutrition, Indian Council of Medical Research, Hyderabad

Dr Parikshit Tank
MD, DNB, FCPS, DGO, DFPMICOG,

Dr. Aparna Sharma
MD, DNB
Assistant Professor, Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi

Dr. A G Radhika
DGO, DNB, MNAMS
Senior Specialist
University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi

Dr Pankaj Malhotra
MD, FRCP (London), FRCP (Glas), FACP,
MRCOG
Chairperson, Safe Motherhood Committee,
FOGSI
IVF & Infertility Specialist, Ashwini
Maternity & Surgical Hospital, Mumbai

Dr Bharati Dhorepatil
DNB (Ob & Gyn), DGO, FICS, FICOG
Dip. Endoscopy (Germany)
Post Gr. Dip. in Clinical Research (UK)
Director & Chief IVF Consultant, Pune
Infertility Center, Pune, Maharashtra

Dr S Shantha Kumari
MD, DNB FICOG
Consultant -Care Hospitals, Hyderabad

Dr Garima Kachhawa
Associate Professor, Obstetrics and
Gynaecology, All India Institute of Medical
Sciences, New Delhi, India

Dr. Vidushi Kulshreshtha
Assistant Professor, Obstetrics and
Gynaecology, All India Institute of Medical
Sciences, New Delhi

Dr Rohini Sehgal
MBBS, MS
Scientist, Obstetrics and Gynaecology, All
India Institute of Medical Sciences, New
Delhi

Dr. Reeta Mahey
Associate Professor, Obstetrics and Gynaecology,
All India Institute of Medical Sciences, New
Delhi, India

Dr. Renu Saxena
MD
Professor and Head, Department of Hematology,
All India Institute of Medical Sciences, New
Delhi
Dr Hrishikesh Pai  
MD, FCPS, FICOG, MSc (USA)  
Secretary General, FOGSI  
Scientific director, The Advanced Fertility Centre' The Lilavati Hospital, Bandra, Mumbai

Dr Parmeet Kaur  
Senior Dietician  
All India Institute of Medical Sciences  
New Delhi -110029, India

Dr Nandita Palshetkar  
MD, FCPS, FICOG  
IVF & Infertility Specialist, Director, Fortis Memorial Research Institute, Gurgaon

Dr Jaydeep Tank  
Deputy Secretary General, FOGSI  
IVF & Infertility Specialist, Ashwini Maternity & Surgical Hospital, Mumbai

Dr Suvarna Khadilkar  
Joint Treasurer, FOGSI  
Consultant Gynecologist & Obstetrician, Bombay Hospital, Marine Lines, Mumbai

Dr Madhuri Patel  
Treasurer, FOGSI  
Honourary Clinical Associate at N Wadia Maternity Hospital, Parel, Mumbai
Introduction

Anemia among pregnant women is a serious global health concern. According to World Health Organization (WHO) report, about 32.4 million pregnant women suffer from anemia worldwide, of which 0.8 million women are severely anemic (1). Moreover, 50% cases of anemia are attributable to iron deficiency anemia (IDA) (1).

When hemoglobin concentrations of an individual are below two standard deviations in comparison to the mean distribution of the normal population who are of same age and gender and live in same altitude, such condition is called Anemia. When this condition arises due to the iron deficiency in the body, it is considered as Iron deficiency anemia (2). Iron deficiency anemia is also defined as hemoglobin of less than 11g% in the first and third trimester of pregnancy and less than 10.5g% in the second trimester of pregnancy (3-6). Iron deficiency anemia during pregnancy increases the risk of low birth weight (LBW), preterm birth, maternal and perinatal mortality, and poor Apgar score (7, 8). An estimate by WHO attributes about 591,000 perinatal deaths and 1,15,000 maternal deaths globally to IDA, directly or indirectly (7). According to Lone et al, anemic women as compared to non-anemic women are at 4 fold higher risk of preterm birth, 1.9 fold increased risk of delivering LBW infants, and 1.8 fold increased risk of having Apgar score <5 at 1 min (8). In a systematic review, a dose-response relationship was observed for an increase in dose of iron supplements and reduction in LBW (9).

It is projected that India has the utmost prevalence of anemia i.e. 57-96.2%, among the South Asian countries (10-14). The prevalence and severity of anemia in India are presented in Table 1.

Table 1 Severity of anemia in national surveys

<table>
<thead>
<tr>
<th>Survey</th>
<th>Anemia of pregnancy (%)</th>
<th>Severity of anemia (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Urban</td>
<td>Rural</td>
</tr>
<tr>
<td>DLHS-2 (2002-04)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NNMB (2003)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NFHS-3 (2005-06)</td>
<td>54.6</td>
<td>59.0</td>
</tr>
</tbody>
</table>
In India, estimated maternal deaths due to IDA is approximately 3,26,000 with an associated disability-adjusted life years (DALYs) of 12,497,000 (7). Anemia in pregnancy can precipitate several complications. Maternal Hb has a positive relationship with the neonatal measures of weight, length and head circumference (15). Another study indicated that maternal anemia in the second and third trimester of gestation affects postnatal infant growth (16, 17). Losses from IDA result in an increase in the cost of up to 4.05% of gross domestic product (GDP) in developing countries, and 1.18% of GDP in India (18). It is known that low socioeconomic status, high parity, nutritional deficiencies, phytate rich Indian diets, malaria, helminthic infections, and inflammatory or infectious diseases further increase the risks of IDA during pregnancy (19-21).

To combat the high prevalence of IDA, several Government programs and state level schemes were rolled out in various states of the India. National Nutritional Anemia Prophylaxis Program 1970, National Anemia Control Program 1991, 12/12 initiative 2007 are some of the nationwide initiatives. Few state-specific schemes include Madilu scheme, Thayi bhagya scheme, and Janani surakshayojana. In spite of Government’s persistent and prolonged efforts, the problem continues to fester as is documented by the recent survey: National Family Health Survey (NFHS-4, 2015-2016); the prevalence is 23.6-61.4% (14). The prevalence is higher in urban areas (23.6-61.7%) as compared to rural areas (19.6-58.1%) (14). Diverse religions, cultures, languages, food habits, lifestyles, and traditions that influence management practices, present a challenge to the implementation of the health program. Hence, there is a continuing requirement for county-specific harmonized guideline for the control of IDA in India. It is expected that this practical approach would promote the implementation of cost-effective evidence-based care.

The present Good Clinical Practice Recommendations (GCPR) from The Federation of Obstetric and Gynaecological Societies of India (FOGSI) for the management of anemia in pregnancy are developed by an experienced panel of gynecologists, obstetricians, and hematologists from across the country. A literature search was carried out electronically in PubMed and Google Scholar. Specific evidence from India (MedIND/IndMED) was identified. Also, a manual search was carried out in key non-indexed journals. Abstracts in the English language
were scanned and included in the formulation of the recommendation. Existing recommendations from national and international guidelines for the management of anemia in pregnancy were also reviewed.

The draft guideline, with proposed GCPR, was reviewed by the members through mail communications and meetings for finalizing consensus on each GCPR for the management of anemia in pregnancy. The modified Grade system was used for classifying the quality of evidence as 1, 2, 3 or 4 (Table 2)(22).

Table 2 Grading of recommendations

<table>
<thead>
<tr>
<th>Grading of recommendations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GRADE A</td>
<td>Strongly recommended “RECOMMENDED”</td>
</tr>
<tr>
<td>GRADE B</td>
<td>Weaker recommendation “SUGGESTED”</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Classification of level of evidence</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 High-quality evidence backed by consistent results from well-performed randomized controlled trials or overwhelming evidence from well executed observational studies with strong effects</td>
<td></td>
</tr>
<tr>
<td>2 Moderate quality evidence from randomized trials</td>
<td></td>
</tr>
<tr>
<td>3 Low-quality evidence from observational evidence or from controlled trials with several serious limitations</td>
<td></td>
</tr>
<tr>
<td>4 Not backed by sufficient evidence; however, consensus reached by expert panel group (Practice point)</td>
<td></td>
</tr>
</tbody>
</table>

Based on clinical experience and expertise
Diagnosis
The continuing problem of IDA in India is attributed to lack of appropriate diagnosis at a suitable age. Iron deficiency (ID) reflects inadequate mobilization of iron stores, leading to impaired “demand to supply” of iron to tissues and red blood cells (RBCs). The requirement for iron greatly increases with each growing stage, including children below 2 years of age, adolescent, pregnant and lactating women. Iron deficiency anemia evolves through three distinct stages. Depletion of storage iron occurs in the first phase (stage I), where the total body iron is decreased but red cell indices and hemoglobin (Hb) synthesis remain unchanged. Both these indices change when the supply of iron to bone marrow is reduced (stage II or iron deficient erythropoiesis). In stage III, eventually, IDA develops due to insufficient supply of iron to sustain a normal Hb concentration. Different phases of IDA are presented in Figure 1.

Figure 1 Various stages of iron deficiency anemia and their indicators (23).
Signs and symptoms

Although Hb test is recommended at first antenatal visit, examination for signs of pallor of the eyelids, tongue, nail beds, and palm should be regularly used. Some ID patients, with or without clinical signs of anemia may have alopecia, atrophy of tongue papillae, or dry mouth due to reduced salivation(24). The symptoms specific to ID include; the syndromes of Plummer-Vinson or Paterson-Kelly (dysphagia with esophageal membrane and atrophic glossitis), gastric atrophy, stomatitis due to rapidly turning over of epithelial cells(25), spoon-shaped nails (koilonychia), and pallor. These changes are caused by a reduction of iron-containing enzymes in the epithelia and gastrointestinal (GI) tract (24). The restless leg syndrome might be striking neurological sequelae prevalent in pregnancy (26). Pica, the eating disorder in which there is an appealing desire to lick or eat non-food items, such as gypsum, chalk, soil, ice (pagophagia) or paper, is prevalent in pregnant women (27-29). Pagophagia (intense desire to eat ice) is quite specific to ID and responds quickly to treatment(30).

Laboratory tests

There are four groups of tests available for assessment of IDA.

1. Red blood cell parameters and indices

Hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), red cell distribution width (RDW), reticulocyte Hb content, % hypochromic cells. Along with the examination of various RBC indices, peripheral blood smear evaluation should also be considered as an essential component of evaluating various hematological disorders (31). Furthermore, examination of blood smear could provide important clues in the diagnosis of anemias. Anecdotal evidence suggest that peripheral blood smear could help in differentiating the IDA from megaloblastic anemia and anemia of chronic disease. Macrocytes, oval shaped macrocytes and hyper segmented neutrophils are associated with megaloblastic anemias (folate or cobalamin deficiency), target cells and pencil cells are associated
with IDA (32, 33). Presence of target cells frequently in the smear rules out anemia of chronic diseases (34). Moreover, poikilocytes (prekeratocytes) are also observed in more numbers in IDA (34).

2. Direct measurement of iron stores

Assessment of serum iron, total iron binding capacity (TIBC), % saturation, serum ferritin, bone marrow biopsy

3. Assessment of heme iron

Estimation of free erythrocyte protoporphyrin (EPP)

4. Assessment of iron uptake

Measuring the soluble serum transferrin receptor (sTfR), and soluble transferrin receptor-log [ferritin] (sTfR-F) index, zinc protoporphyrin (ZPP).

   1. Red blood cell parameters and indices

A primary step in the diagnosis of IDA is to consider the complete blood count (CBC) including Hb, MCV, MCH, and MCHC (35-37). It is simple, inexpensive, rapid to perform and helpful for early prediction of IDA.

Changes in Hb concentration and hematocrit occur only in late stages as shown in Figure 1; both these tests are late indicators of ID. Nevertheless, these tests are important for determining IDA. Low Hb with a reduced MCV is usually the initial finding on a routine CBC. The severity of anemia is based on the patient’s Hb/hematocrit level as mentioned in Table 3a and Table 3b by WHO and ICMR, respectively. Indeed, a recent study from India demonstrated that various hematological parameters especially sTfR, serum erythropoietin, serum ferritin and sTfR/log ferritin levels correlate with the severity of anemia (38).

Table 3a Hemoglobin cut off in pregnancy anemia (WHO)(39)
Pregnancy state | Normal (g/dL) | Mild (g/dL) | Moderate (g/dL) | Severe (g/dL) |
--- | --- | --- | --- | --- |
First trimester | 11 or higher | 10-10.9 | 7-9.9 | Lower than 7 |
Second trimester | 10.5 or higher | 10-10.9 | 7-9.9 | Lower than 7 |
Third trimester | 11 or higher | 10-10.9 | 7-9.9 | Lower than 7 |

Table 3b Hemoglobin cut off for anemia (ICMR) (40, 41)

| Normal (g/dL) | Mild (g/dL) | Moderate (g/dL) | Severe (g/dL) | Very Severe (g/dL) |
--- | --- | --- | --- | --- |
11 or higher | 10-10.9 | 7-10 | <7 | <4 |

Altitude above sea level and smoking are the known modifiers of Hb concentration (42). The rising maternal blood volume and iron requirements of the fetus are responsible for the dramatic change in Hb concentration in healthy women. The Hb concentrations decrease in the first trimester, which continues to decline and reach their lowest point in the second trimester, and start to increase again in the third trimester. Currently, the Hb cut-off according to trimester has not been defined by WHO, however, a generic value of -1.0 g/dL has been suggested for unknown trimester. Nonetheless, Nester P has developed Hb adjustment table for all trimesters; see table 4 (43). Hemoglobin concentration is the commonest hematological estimation and there is a strong correlation between Hb concentration and serum ferritin levels (44). Generally recommended methods of Hb estimation are cyanmethemoglobin and the HemoCue® system (39).

Table 4. Hemoglobin adjustment for pregnant women living at sea level (43)
<table>
<thead>
<tr>
<th>Stage of Pregnancy (Trimester)</th>
<th>Hemoglobin g/ dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>First</td>
<td>-1.0</td>
</tr>
<tr>
<td>Second</td>
<td>-1.5</td>
</tr>
<tr>
<td>Third</td>
<td>-1.0</td>
</tr>
<tr>
<td>Trimester unknown</td>
<td>-1.0</td>
</tr>
</tbody>
</table>

Mean corpuscular volume is the measure of the average RBC volume, and MCHC is the measure of the concentration of Hb in a given volume of packed RBCs. It is important to note that up to 40% of patients with true IDA would have normocytic erythrocytes (i.e. a normal MCV does not rule out IDA) (24). Red cell distribution width has a better sensitivity than MCV for the diagnosis of IDA (45).

The RDW is a measure of the change in RBC width and is used in combination with the MCV to distinguish an anemia of mixed cause from that of a single cause. Increased RDW represents variance in the RBC volume distribution, similar to a peripheral blood smear anisocytosis. In the initial stages of IDA, there is a fall in MCV accompanied with increasing RDW values due to a preponderance of microcytes (46, 47). Following treatment, marked reticulocytosis occurs in the first 4 weeks, manifested as a sudden increase in RDW, sometimes to over 30% (48). Thus, falling MCV accompanied by a rising RDW should alert the clinician to the presence of possible IDA which is then confirmed by marked RDW increase occurring early after the initiation of therapy (37). A few studies have reported sensitivity and specificity, respectively, of RDW in the diagnosis of IDA in pregnancy; Sultana et al, 97.4% and 83.2%; and Tiwari et al, 72.8% and 82.4% (44, 45).

It is noteworthy that microcytosis observed in the peripheral smear may be seen even before abnormalities in CBC are developed. If the patient has coexistent folate or vitamin B12 deficiency, the peripheral smear would show a blend of microcytic and macrocytic hypochromic erythrocytes, along with normal MCV (37). Furthermore, the presence of microcytic hypochromic red cells and typical “photo pencil cells” are indicative of IDA (46). It is common for the platelet count to be greater than 450,000/µL in the presence of IDA, though, the red cell count falls.
Iron deficiency anemia is characterized by microcytic RBCs. Other conditions causing microcytic RBCs include anemia of chronic disorders, β-thalassemia, and sideroblastic anemia. Differential diagnosis of thalassemia and iron deficiency anemia is of great clinical importance since prognosis and treatment are distinct. Several diagnostic indices have been developed to distinguish IDA from thalassemia trait (47, 48). The development of an index with good diagnostic accuracy based only on parameters derived from the red blood cell count obtained using simple counters would be useful in the clinical routine. Indeed, a meta-analysis demonstrated that the ratio of microcytic to hypochromic RBCs (M/H ratio) (diagnostic odds ratio (DOR) =100.8) and the RBC index (DOR=47.0) have shown good performance in differentiating thalassemia and iron deficiency anemia (49). All the tests described above helps differential diagnosis of various microcytic RBCs etiologies as shown in Table 4.

Table 4 Differential diagnosis of various microcytic RBCs etiologies (50-52)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>IDA</th>
<th>BT</th>
<th>SA</th>
<th>ACI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>Decreased</td>
<td>Normal or decreased</td>
<td>Normal or decreased</td>
<td>Normal or decreased</td>
</tr>
<tr>
<td>Ferritin</td>
<td>Decreased</td>
<td>Normal</td>
<td>Normal or increased</td>
<td>Normal or increased</td>
</tr>
<tr>
<td>Serum iron</td>
<td>Decreased</td>
<td>Normal or increased</td>
<td>Normal or increased</td>
<td>Normal or decreased</td>
</tr>
<tr>
<td>TIBC</td>
<td>Increased</td>
<td>Normal</td>
<td>Normal</td>
<td>Slightly decreased</td>
</tr>
<tr>
<td>TS</td>
<td>Decreased</td>
<td>Normal to increased</td>
<td>Normal to increased</td>
<td>Normal to slightly decreased</td>
</tr>
<tr>
<td>sTfR</td>
<td>Increased in severe IDA</td>
<td>&gt;100 mg/L</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>FEP</td>
<td>Increased</td>
<td>Normal</td>
<td>Normal</td>
<td>Increased</td>
</tr>
<tr>
<td>MCV</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Normal</td>
<td>Normal or decreased</td>
</tr>
<tr>
<td>RDW</td>
<td>Increased</td>
<td>Normal to increased</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>Decreased</td>
<td></td>
<td>-</td>
<td>Normal or decreased</td>
</tr>
<tr>
<td>Mentzer index</td>
<td>Increased (&gt;13)</td>
<td>Decreased (&lt;13)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

ACI, acute chronic inflammation; BT, β-thalassemia; IDA, iron deficiency anemia; FEP, free erythrocyte protoporphyrin; MCV, mean corpuscular volume; RDW, red cell distribution width; SA, sideroblastic anemia; sTfR, soluble transferrin receptor; TIBC, total iron binding capacity; TS, transferrin saturation.
However, in low-resource settings like India, where these tests are not easily available, the RBC indices are of great value for primary diagnosis which can reduce unnecessary investigative costs. Of all available indices, the Mentzer index (MCV/RBC count) has been shown as the most reliable index with high sensitivity (48,53). Mentzer Index>13 indicates IDA and <13 indicates β-thalassemia. Furthermore, two studies from Middle-East have reported RBC count as above $5 \times 10^6 \text{mm}^3$ in β-thalassemia subjects whereas in IDA patients it is below that value (54, 55).

**Serum ferritin**

Ferritin is a sensitive indicator of IDA in pregnant women(45, 56, 57). Serum ferritin reflects ID in the absence of inflammation, with the advantage of steady concentration even on the recent intake of iron rich foods. During pregnancy, in women with adequate iron stores, serum ferritin initially rises and later gradually falls by 32 weeks (due to hemodilution), followed by a slight rise in the third trimester. Fall in serum concentration below 15 μg/L indicates iron depletion in all stages of pregnancy(58). However, treatment needs to be initiated when the concentration falls below 30μg/L, as this indicates early iron depletion(58, 59).

**Soluble transferrin receptor (sTFR)**

It is a sensitive measure of tissue iron supply but is an expensive test. It is a transmembrane protein which transports circulating iron into the RBCs and is expressed on erythrocyte membranes; sTfR and total transferrin concentrations are directly proportional. The assay is not standardized(60). Cutoffs of sTfR (and, thus, the sTfR–F) depend on the assay used, which is a key limitation. There is a gradual increase in mean sTfR concentration as pregnancy progresses. The increase is mostly influenced by increased erythropoietic activity than by iron depletion(61).

**Serum Iron, and total iron binding capacity (TIBC)**

Serum iron and TIBC are the other independent indicators of iron stores or availability. The TIBC measures the obtainability of iron-binding sites. Transferrin, a specific carrier protein transports extracellular iron in the body. Therefore, TIBC is the indirect measure of transferrin levels
that rises as serum iron concentration (and stored iron) declines. The TIBC decreases with malnutrition, inflammation, chronic infection, and cancer (62).

_Erythrocyte Zinc Protoporphyrin (EPP) and Zinc protoporphyrin (ZPP)_

The erythrocyte ZPP is formed when zinc is incorporated into protoporphyrin in place of iron during the biosynthesis of heme. Short supply of iron as in IDA increases ZPP production and elevates ZPP/heme ratio whereas in normal condition the reaction of ZPP with iron predominates (62). Before the onset of anemia, ZPP/heme reflects iron status and detects ID. This test is most accurately reported as the ZPP or ZPP/heme ratio. It is a sensitive test, but with limited specificity, because ZPP increases in the settings of inflammation, lead poisoning, anemia in chronic disease, and hemoglobinopathies (63). Normal value of ZPP< 2.3 micrograms ZPP/g Hb.

_Reticulocyte hemoglobin content_

Reticulocyte Hb concentration determines the amount of iron presented to the bone marrow for uptake into new RBCs. This test is not commonly available. The sensitivity and specificity of this are analogous to those of serum ferritin (64).

_Bone Marrow biopsy_

Bone marrow biopsy should be considered to make a definitive diagnosis of IDA when the diagnosis remains ambiguous even after the analysis of laboratory results. It is indicated when there is no response to treatment or to rule out other conditions. The absence of stainable iron is the ‘gold standard’ for diagnosis of IDA.

_Trial of Iron therapy_
In situations with low Hb or hematocrit, a presumptive diagnosis of IDA is supported by a response to iron therapy. If the patient is known to have hemoglobinopathies, serum ferritin has to be checked to rule out microcytic or normocytic anemia before starting iron therapy to avoid iron overload. An increase of at least 1 g/dL in hemoglobin or 0.03 l/l in hematocrit after 1 or 2 months of supplementation shows an adequate response to treatment and confirms the diagnosis of IDA (2, 3, 4, 36, 65). However, when multiple etiological factors cause anemia, iron supplementation could only correct the hemoglobin deficit partially. Therefore, based on the prevalence of possible etiological factors, concurrent interventions such as using micronutrients other than iron, or control of infections such as malaria or hookworm might be needed (2).

Management
Management of ID can be achieved at two levels, at the individual patient or at public health level. Prevention strategies developed by WHO comprise food-based approach, iron supplementation, improvement in health services and sanitation. Other strategies, e.g. control of hookworm, malaria, and parasitic infestations are also required to prevent IDA in Indian women (66).

Food-based strategies
Dietary modification/improvement

The physiological demand for iron during pregnancy is 3 times higher than in non-pregnant women, and it increases as pregnancy progresses(58, 67). The net iron requirements for pregnancy has been calculated as 840 mg taking into account the requirements for fetus, placenta, expansion of maternal erythrocyte mass, and final losses due to delivery(68). Though iron requirements decrease during the first trimester, there is an increase of 4-6 mg/day in the second and third trimesters which may reach to 10 mg/day during the last 6–8 weeks of pregnancy(69). The extent of iron absorption in pregnancy also needs to be contemplated. The iron absorption has been found to decrease during the first trimester of pregnancy, which rises during the second, and this increase lasts the remainder of pregnancy (69).

The dietary modification involves improving intake of iron by increasing the quantity of iron rich food and practices that increase the absorption of iron (70). The etiology of anemia in India is multifactorial with low iron bioavailability as a major etiological factor(71). Moreover, non-heme
iron, a poorly absorbed form of iron, from cereals, pulses, vegetables and fruits contribute about 90-95% of total daily iron in Indian diets(71). Non-heme iron (present in plant-based foods) absorption is inhibited by phytic acid (6-phosphoinositol) which is found in whole grains, lentils, and nuts. In addition, polyphenols, such as tannic and chlorogenic acids found in coffee, tea, red wines, and a variety of vegetables, cereals, and spices also inhibit iron absorption. They are capable of forming complexes with iron at physiological pH of 7.4 and alter the equilibrium concentration of free iron and thus influence bioavailability. Promoting the use of iron absorption enhancers like ascorbic acid is an effective way of increasing bioavailability of iron and a resultant improvement in Hb level (72-75). Nair et al., demonstrated >100% increase in bioavailability with 100 g of guava fruit included in the regular meal. In this study, the iron absorption from the modified meal was greater when compared with a regular meal (23.9±11.2% vs 9.7±6.5%, p<0.05) (76). Because phytate is a known iron absorption inhibitor, consumption of phytate rich food should be discouraged with meals. Other food items that need to be eluded are tannins present in coffee, cocoa and tea; calcium, particularly in milk and milk products; phosphates in egg yolk; and oxalates in vegetables(77, 78).

There is evidence that dietary modification and awareness education among pregnant women improve maternal and neonatal outcomes (79-82). Individual counseling with nutrition education (NE) along with weekly reinforcement significantly increased mean Hb (g/dL) levels (Post-NE vs Non-NE, 9.65±0.97 vs 7.85±1.58, p<0.001) and decreased anemia prevalence (Post-NE vs Non-NE, 78.7% vs 96.0%) in post-NE group in nutritional status during pregnancy in a study by Garg A et al. (83)

Food fortification

Food fortification is the concept of combining a vehicle (probably commonly consumed food items) and a nutrient together and is probably the most cost-effective long-term approach in improving the iron status during pregnancy at the national level(84-86). When accompanied with supplementation, food fortification can be an effective way in managing IDA in women with pregnancy (87). Of various fortifying iron compounds, sodium iron ethylenediaminetetraacetic acid (NaFeEDTA) is most frequently used owing to its effectiveness with a diet rich in phytates such as sugar, curry powder, soy sauce, fish sauce and maize flour (88-92). Micronized ground ferric pyrophosphate is another iron salt
used for fortification of color-sensitive food vehicles, such as salt in Africa (93) and rice in India (94). Bio-fortification is a recent approach in iron fortification of wheat, bean, cassava, maize, rice, and yam (95).

Food fortification was found to be non-inferior to iron and folic acid (IFA) supplementation in improving Hb concentration and decreasing the prevalence of IDA in pregnant women (96-105). Double fortified salt (DFS) has been demonstrated to significantly increase mean Hb in pregnant women consuming DFS than women not consuming fortified salt (+0.42 g/dL vs 0.20 g/dL, p<0.001). Further, DFS provided additional ~93 mg of iron within 6 months of supplementation (87).

Supplementation
The average daily requirement of iron increases from 4-6 mg/day in the second and third trimesters to 10 mg/day during the last 6–8 weeks of pregnancy (69). These requirements are unlikely to be met by the diet alone because of poor accessibility, availability, and affordability of diversified food (106). Hence, regular iron supplementation is necessary for pregnant women to prevent IDA. The supplementation to prevent anemia targets at improving the ID and it may be community-based initiative while therapeutic supplementation aims at treating established IDA, which is a part of the healthcare delivery system (2).

Oral supplementation
A Cochrane systematic review evaluated the efficacy of daily iron supplementation alone or along with folic acid or other micronutrients compared with placebo or no iron in pregnant women. Prophylactic iron supplementation displayed a significant decrease in the risk of maternal anemia (70%), ID and IDA (57%) at term. Iron treated women had a greater probability of higher Hb concentrations at term and in the postpartum period. Nonetheless, they were at relatively high risk of Hb concentrations >13g% during pregnancy, and at term. Women taking iron supplements had lower incidence of giving birth to LBW babies (8.4% vs 10.3%, RR 0.84, 95% CI, 0.69 to 1.03), preterm babies (RR 0.93, 95% CI, 0.84 to 1.03) and also slightly heavier babies (mean difference 23.75g, 95% CI, -3.02 to 50.51). There were no significant differences between groups for congenital anomalies, neonatal death, and maternal death (107). Another systematic review and meta-analysis, which included 44 cohort studies in addition to 48 randomized clinical trials (RCTs) evaluating impact of prenatal iron supplementation on adverse pregnancy
outcomes, found an increase in maternal Hb by 0.459 g/dL, reduction in the risk of anemia (RR 0.50, 95% CI, 0.42 to 0.59), ID (RR 0.59, 95% CI, 0.46 to 0.79), IDA (RR 0.40, 95% CI, 0.26 to 0.60), and LBW (RR 0.81, 95% CI, 0.71 to 0.93) compared to controls. Of particular note, the risk of LBW (adjusted OR 1.29, 95% CI, 1.09 to 1.53) and preterm birth (adjusted OR 1.21, 95% CI, 1.13 to 1.30) were higher with anemia in the first and second trimester as shown by a meta-analysis of cohort studies. The exposure-response (dose response) analysis displayed increase in birth weight of 15.1 g (6.0 to 24.2, linear trend p=0.005), decrease in risk of LBW by 3% (RR 0.97, 95% CI, 0.95 to 0.98, linear trend p<0.001), for every 10 mg increase in iron dose/day, up to 66 mg/day. Moreover, after adjustment for dose, the duration of the supplement was not significantly associated with the outcomes as shown by an increase in birth weight by 14.0 g (6.8 to 21.8, linear trend p=0.002) for each 1 g/dL increase in mean Hb(9).

Daily Vs Intermittent
A recent Cochrane systematic review has shown similar maternal and infant outcomes with both intermittent and daily supplementation. Intermittent supplementation was associated with fewer side effects, although, the risk of mild anemia near term was increased. Intermittent supplementation has been proposed as a feasible alternative to daily supplementation for those pregnant women who are not anemic and have an adequate antenatal care (108). WHO recommends once a week intermittent iron and folic acid supplementation (120 mg elemental iron and 2.8 mg folic acid) in non-anemic pregnant women and adolescents (109). MoHFW recommend intermittent iron and folic acid supplementation (100 mg elemental iron and 0.5 mg folic acid) in all females of reproductive age (15-45 years) (110).

Iron Preparations
There are various iron salts commonly used for the treatment of anemia in India. A systematic review, which included about 10,695 patients, found extended-release ferrous sulphate with mucoproteose to be the most tolerated oral iron supplement of the various formulations evaluated (111). Numerous studies in India have been found to evaluate comparative efficacy and tolerability of different iron supplements as presented in Table 6.
Table 6 Summary of comparative studies in India on oral iron preparations

<table>
<thead>
<tr>
<th>Author /year</th>
<th>N</th>
<th>Objective</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcome</th>
<th>Results</th>
</tr>
</thead>
</table>
| Pyarelal, 2015(112)   | 90 | CI vs FS & FF: efficacy in IDA     | CI: 100mg OD for 2 months. **Inclusion criteria** Gestational age 14-20 wks Hb (9 - 11g/dL) | FS: 200mg t.i.d. FF: 200mg b.i.d. for 2 months | ↑Hb (30 & 60D). ADR | • Rise in Hb was seen with all preparations  
• ↑Hb at 30 D with CI : from 8.69±0.77 baseline to 10.31±0.71, with FS: from baseline 8.89±0.63 to 9.68±0.74, with FF 8.43±0.89 to 9.12±0.87 (p<0.05)  
• ↑Hb at 60D with CI : from 8.69±0.77 baseline to 11.67±0.68 at 60 D, with FS: from baseline 8.89±0.63 to 10.21±0.73, with FF 8.43±0.89 to 10.03±0.91 (p<0.05)  
• ↑Hb at 60D was higher with CI than FS and FF (p<0.05)  
• GI disturbances less in CI as compared to the others.  
• CI is effective and better tolerated than others. |
| Singhal SR et al, 2015(113) | 250 | Various OI salts: efficacy & safety | FS (100mg), FF (100mg), FA (100mg), FB (30 mg), SoF (33 mg) **Inclusion criteria** Gestational age 16-28 wks Hb (7-10g/dL) | -             | ↑Hb (30 & 60D), SF (60D) ADR | • Mean↑Hb at 60D(g/dL): FS, 0.93±0.27; FF, 1.06±0.28; FA, 1.13±0.35; FB, 1.11±0.27; SoF, 1.09±0.31(p<0.001)  
• Mean↑SF at 60D (ng/ml): FS, 12.19±5.01; FF, 12.65±5.77; FA, 13.44±7.89; FB, 13.47±7.03; SoF, 11.95±3.95(p<0.001)  
• % S/E : FS, 32; FF, 40; FA, 22; FB, 26; SoF, 14  
• FA & FB are more effective than FS. SoFless S/E |
| Geetha R et al, 2014(114) | 60 | CI vs FS vs FF: efficacy & tolerability | CI: 100mg OD for 2 months. **Inclusion criteria** Gestational age>14 wks Hb (9 - 11g/dL) | FS: 200mg t.i.d. FF: 200mg b.i.d. for 2 months | ↑Hb (30 & 60D) ADR | • ↑Hb at 60D (g/dL): CI, 8.62±0.74 to 11.8±0.60; FS, 9.12±0.66 to 10.53±0.76; FF, 8.63±0.94 to 10.44±0.98(p<0.05)  
• GI disturbances less in CI as compared to the others  
• CI showed highly significant ↑Hb & superior in efficacy & better tolerated than others |
<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Duration (Ref)</th>
<th>Study Design</th>
<th>Methodology</th>
<th>Inclusion Criteria</th>
<th>Study End Points</th>
</tr>
</thead>
</table>
| Sagoonkar S et al, 2009 (115) | 150 FF vs CI: efficacy & tolerability | FF: 152mg (app. 50mg elemental iron) + folic acid 750µg + zinc sulphate 61.8mg) b.i.d for 12 wks. | **Inclusion criteria** Gestational age >14 wks of amenorrhea & pregnancy with Hb (7-10 g/dL) Target Hb: 11 g/dL. | **↑ Hb (2, 4, 8 & 12 wks)** ADR | • Mean↑Hb at 12 wks: 3g/dL (FF) & 1.489g/dL( CI) (p<0.0001)  
• Achieved target Hb: 90.2% (FF) & 20.83%(CI)  
• FF showed better outcome than CI group with respect to response to therapy (p<0.0001) & tolerability (p=0.002)  
• Tolerability: 65.3% (FF) & 34.7% (CI)  
• ADR more in CI group.  
• FF is not only significantly superior in efficacy but is better tolerated than CI. |
| Saha L et al, 2007 (116) | 100 IPC vs FS: efficacy, safety, compliance & cost effectiveness | IPC: 100mg elemental iron + folic acid 500 µg daily for 8 wks (A) | **Inclusion criteria** 14-27 wks gestation, with Hb< 9g/dL & SF< 12 µg/L, | **↑ S.Iron (A vs B) (p<.001): 67.29±9.12 to 105.61±15.22 µg/dL vs 65.75±21.45 to 108.88±42.5 µg/dL**  
**↑ SF (A vs B) (p<.001): 10.93±4.14 to 33.52±10.57 ng/ml vs 11.38±8.5 to 28.22±10.40 ng/ml**  
**ADR (A vs B) (p<.001): 31 VS 78%**  
**Compliance (A vs B): 91% vs 87% (p<0.05)**  
**Cost (A vs B ):Rs 237.08±47.25 vs Rs 169.98±75.51 (p<.001)**  
**IPC considered as alternative for the treatment of IDA intolerance to other iron (ferrous form)** | | |
| Shatruagna V et al, 1999 (117) | 115 Various iron formulations: tolerance | FS tablets (60, 120 & 180mg of elemental iron),60mg of elemental iron (FS salt, FF tablets & syrup) excipients added to pure FS salts, powdered FS tablets, FS | - | **Bioavailability & S/E** | • Increasing the dose improves the bioavailability of iron, but associated with unacceptable S/E.  
• Liquid formulations of iron had a better bioavailability (FF syrup and gelatin capsules most superior) |
<table>
<thead>
<tr>
<th>Study</th>
<th>Methodology</th>
<th>Inclusion criteria</th>
<th>Outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kambar et al, 2013 (118)</td>
<td>IPC vs FS: efficacy, safety, compliance &amp; cost effectiveness</td>
<td>IPC: 100mg elemental iron + folic acid 500µg OD for 6 weeks (A) Inclusion criteria: 14 to 20 wks of gestation, Hb: 6.5-8 g/dL (moderate anemia) FS: 60mg elemental iron + folic acid 500 µg b.i.d for 6 wks (B)</td>
<td>After 6w, Hb, PCV, MCHC &amp; Se. iron. ADR</td>
<td>• Mean ↑Hb (A vs B): 1.348 vs 1.05 g/dL (p&lt;0.05) • Mean ↑% PCV (A vs B): 4.2 vs 3.14 (p&lt;0.05) • Mean ↑MCHC (A vs B): 0.99 vs 0.66 g/L (p&gt;0.05) • Mean ↑Se. iron (A vs B): 3.7 vs 0.5 µg/dL (p&lt;0.001) • ADR (A vs B): 20% vs 51% (p&lt;0.001). • Compliance (A vs B): 91% vs 87% (p&lt;0.05) • Cost (A vs B): Rs 207.08 ± 47.25 vs 139.98 ± 75.51 (p&lt;0.001) • IPC is better alternative to FS as safe &amp; compliance.</td>
</tr>
<tr>
<td>Patil SS et al, 2013 (119)</td>
<td>Various iron salts: efficacy, tolerability &amp; cost</td>
<td>FF, FB, &amp; CI (each 100 mg) Folic acid 1.5mg, Vit-B12 10µg administered OD to all. Inclusion criteria: Gestational age 12-22 wks, Hb &lt;10g/dL &amp; microcytic hypochromic anemia Study period: 3 months</td>
<td>-</td>
<td>• Significant ↑Hb in all groups (p&lt;0.001) • ↑SF with FF significantly more than others (p&lt;0.05). • Nausea (p&lt;0.05) &amp; epigastric pain (p&lt;0.001) was significantly high with FF as compared with other. • FF (Rs. 1.14/unit) cheapest drug than others. • FF considered as best cost effective medication &amp; tolerable S/E for treatment &amp; prevention of IDA.</td>
</tr>
<tr>
<td>Sarkate P et al, 2007 (120)</td>
<td>SoF vs FF: efficacy</td>
<td>Group A: SoF (33mg of elemental iron) + Vit-B12 (15µg) + folic acid (1.5mg) b.i.d. Group B: SoF (66mg of elemental iron) + Vit-B12 (15µg) + folic acid (1.5mg) b.i.d. Inclusion criteria: Gestational age 12-26 wks Hb</td>
<td>Group C: FF (100mg of elemental iron) + Vit-B12 (15µg) + folic acid (1.5mg) b.i.d. Hb, RBC count, MCV, MCH&amp;C, MCH &amp; SF, Se. iron, TIBC &amp;</td>
<td>• Mean ↑Hb at 75 D (p &lt; 0.05) (g/dL): 1.79 (A), 1.84 (B) &amp; 1.63 (C). • Low doses of SoF (33mg and 66mg of elemental iron b.i.d) produce comparable results as a higher dose of FF (100mg elemental iron b.i.d) • SoF appears to be effective in improving Hb profile in pregnant anemic women &amp; is tolerated well.</td>
</tr>
<tr>
<td>Study</td>
<td>Patients</td>
<td>Inclusion Criteria</td>
<td>Treatment</td>
<td>Hb (30D) &amp; Cost Effectiveness</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>--------------------</td>
<td>-----------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Angadi E et al, 2015(121)</td>
<td>150</td>
<td>Gestational age 14-24 wks Hb &gt; 8g/dL &amp; severe intolerance of OI</td>
<td>Group A: FA 100mg + folic acid 1.5mg, Group B: FF 100mg + folic acid 1.5mg, Group C: IPC 100mg + folic acid 1.1mg.</td>
<td>Mean ↑Hb at 30D was more with A (1.569g/dL), followed by B (1.097g/dL) and C (0.48 g/dL). (p&lt;0.001)</td>
</tr>
</tbody>
</table>

ACER, average cost-effectiveness ratio; CI, carbonyl iron; FS, ferrous sulphate; OD, once daily; ADR, adverse drug reaction; FF, ferrous fumarate; FA, ferrous ascorbate; FB, ferrous bisglycinate; SoF, sodium feredetate; OI, oral iron; SF, serum ferritin; S/E, side effects; IPC, iron polycarboxymaltose; PCV, packed cell volume; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; TIBC, total iron binding capacity; TSAT, transferrin saturation.
In an RCT, comparing various iron supplements in pregnant women, ferrous ascorbate and bisglycinate were more effective (mean Hb rise in g/dL, 1.13±0.35, p=0.024; 1.11±0.27, p=0.014; respectively) and better tolerated than ferrous sulphate (113). The PERFECT trial, a multi-centric RCT, compared the efficacy and tolerability of ferrous fumarate with carbonyl iron for the treatment of IDA in pregnancy, demonstrated a significantly greater increase in Hb in the patient with ferrous fumarate compared with carbonyl iron. Ferrous fumarate was better tolerated than carbonyl iron as shown by patient global assessment of response to therapy (PGART) score (1.416 vs 1.750, p<0.0001) and patient global assessment of tolerability to therapy (PGATT) score (1.416 vs 1.652, p=0.002) scales response (122). A comparable rise in Hb was found in pregnant women treated with low doses of ferrous fumarate than ferrous sulphate in a double-blind RCT in India (120). Few studies have found iron polymaltose complex to be more effective and better tolerated than ferrous sulphate in pregnant women (116, 118, 123). Ferrous calcium citrate has been shown to increase Hb by 0.46 to 0.5 g/dL per week with no GI side-effects in a clinical trial (124). The results were supported by another study, which demonstrated an increase in Hb by 0.8-2 g/dL (125). Delayed release preparations of several ferrous salts are available, e.g. ferrous calcium citrate multi-layered system. Present evidence does not allow for arriving at any conclusion on the most effective and better-tolerated iron formulation for use in pregnant women in India.

The GI side effects have been reported to be associated with poor compliance to iron supplementation in pregnant women in India (126). A subgroup analysis of pooled data from 7 RCTs in a systematic review has demonstrated a statistically significant increased risk of GI side effects with ferrous sulphate (OR3.33, 95% CI, 1.19-9.28, p= 0.02, I² = 66.1%) in pregnant women (n=1028). These side effects include diarrhea, constipation, abdominal pain, flatulence, nausea, black or tarry stools and heartburn (127). Drug interactions are also a major concern of oral iron pills as they interact with many drugs (128).

Patient instructions for oral iron supplementation should include

1. Taking tablets on an empty stomach or at least one hour after a meal (in case of vomiting, nausea or gastritis) for better absorption
2. Avoiding consumption with tea, coffee, milk or calcium tablets
Iron Prophylaxis

Prophylactic supplementation of all pregnant women with 60 mg iron and 400 µg folic acid daily, till term in pregnancy and continuation of similar dose during lactation for 3 months in countries where prevalence is >40% is recommended by WHO (129). The 2013 Ministry of Health and Family Welfare (MoHFW) guideline recommends 100 mg of iron and 500 µg of folic acid daily at least for 100 days starting after the first trimester, at 14-16 weeks of gestation, followed by the same for 6 months in the post-partum period (130, 131). Daily supplementation of 120 mg of elemental iron and 400 µg of folic acid is recommended by WHO in established mild to moderate anemia in pregnancy. The 2013 MoHFW guideline recommend two IFA tablets per day for at least 100 days for the treatment of mild anemia, intramuscular (IM) iron therapy in divided doses with oral folic acid in moderate anemia. Both guidelines recommend offering standard prophylactic dose after the Hb is normalized for remaining term of pregnancy (130, 131). These recommendations are summarized in Table 7.

Table 7 Summary of recommendations by WHO and MoHFW.

<table>
<thead>
<tr>
<th></th>
<th>During pregnancy</th>
<th>Postpartum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Prophylaxis</td>
<td>Treatment</td>
</tr>
<tr>
<td>WHO</td>
<td>Daily 60 mg iron+400 µg folic acid till term</td>
<td>Daily 120 mg iron+400 µg folic acid till term</td>
</tr>
<tr>
<td>MoHFW</td>
<td>Daily 100 mg iron+500 µg folic acid- for 100 days starting after the first trimester, at 14-16 weeks of gestation</td>
<td>● Mild anemia- 2 IFA tablets/day-100 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Daily 100 mg iron+500 µg folic acid- 6 months</td>
</tr>
</tbody>
</table>

Recommendations:

1. In pregnant women with established mild to moderate anemia, with a period of gestation less than 30-32 weeks, and those who respond to a trial of oral iron, the treatment should continue with 100 mg elemental iron twice daily and 500 µg of folic
acid with an assessment for therise in hemoglobin. A repeat hemoglobin test is recommended after 4 weeks of oral iron. (Grade A, level 3)

1.2. After achieving the normalization of hemoglobin a prophylactic daily iron supplementation (60-100 mg of iron and 500 µg of folic acid) is recommended for at least 6 months during pregnancy and should be continued in postpartum for another 6 months.

1.3. Pregnant women on oral iron supplements should be counseled to consume the tablets before meal or at least one hour after the meal along with supplements like Vitamin C to enhance absorption.(Grade A, level 3)

Parenteral iron

Indications

A major drawback of oral iron is reduced compliance owing to poor tolerability and side effects. The GI adverse effects of oral iron may further exacerbate the pregnancy associated GI disturbances which includes indigestion, constipation, nausea, vomiting, and reflux esophagitis (132). Hence, parenteral iron could be an alternative to oral iron in patients who are unable to tolerate oral iron, and are non-compliant (58) or need rapid restoration of iron stores. Parenteral iron may be used from the second trimester and during the postpartum period (58).

Prerequisites for parenteral iron therapy

Diagnosis of IDA needs to be confirmed before starting parenteral therapy. The infusion should be carried out only in a health facility with adequate supervision and availability for the management of anaphylaxis (133, 134). Sensitivity test prior to infusion is recommended. Contraindications to parenteral iron are

1. A history of anaphylactic reactions to parenteral iron therapy.
2. First trimester of pregnancy, chronic liver disease and active infection (acute or chronic). No evidence on the use of IV iron in the first trimester of pregnancy is present. (58, 135, 136).
3. Oral Iron should be stopped at least 24 hours prior to therapy to avoid toxic reaction (137).

Calculation of Dose of Parenteral Iron (138)
Required iron dose (mg) = \((2.4 \times (\text{target Hb-actual Hb}) \times \text{pre-pregnancy weight (kg)}) + 100\) mg for replenishment of stores

**Intramuscular administration**

Intramuscular iron has been shown to be more effective than oral iron in some RCTs. In two RCTs, IMiron (2 or 3 doses of 250 mg iron at monthly intervals) significantly improved ferritin level compared with oral iron and proposed it as an alternative in patients with poor tolerability to oral iron (139, 140). Similar results were obtained in another study which used three IM doses of 150 mg each at 4 weekly intervals vs daily 100 mg elemental iron (141). Intramuscular iron preparations available in India are iron sorbitol, iron dextran and iron polymaltose.

Test dose

All new patients planned for dextran should be given a test dose of 25 mg and they should be observed at least 1 hour for any adverse event. Uneventful test doses do not eliminate a probability of experiencing hypersensitivity reactions later with either the first dose or subsequent doses. A repeat test dose is advised in patients with an interval of no treatment who have been prescribed repeat doses of iron dextran.

The MoHFW guidelines for treatment of IDA in pregnancy recommend IM iron following a test dose as treatment of choice for moderate anemia in pregnancy (131).

**Adverse effects**

Adverse effects include mild joint pains and discoloration at the injection site, severe reactionssuch as allergy, itching, fever, lymphadenopathy, arthralgia, headache, malaise and anaphylaxis (142).

**Intravenous iron administration**

Iron sucrose is the most commonly used preparation for IV infusion and is safe with fewer adverse events (143). It is rapidly taken up by the bone marrow for erythropoiesis and the reticuloendothelial system for storage. The advantage of iron sucrose is that it does not require to administer a test dose (144) and adverse reactions are virtually unknown (142). In an Indian study (n=100), pregnant women with hemoglobin (5-9 g%) and with iron deficiency, intravenous iron sucrose complex (200 mg twice weekly) produced a significant improvement in hemoglobin (Hb raised from 7.63 ± 0.61 to 11.20 ± 0.73 g% (P<0.001) after 8 weeks of therapy) (143). A recent systematic review has shown a significant increase in Hb (mean difference 0.85 g/dL; 95% CI, 0.31–1.39; p=0.002) and ferritin levels (mean difference 63.32; 95% CI, 39.46–87.18; p<0.00001), with fewer adverse effects (RR, 0.50; 95% CI,
0.34–0.73; p=0.0003) in the IV compared to oral group. Intravenous iron sucrose was more efficacious with few adverse effects than oral formulation in pregnant women with poor tolerability of oral iron and who required immediate replenishment of iron stores (144). Numerous studies in India have evaluated the effectiveness of IV iron as a first line treatment in moderate to severe anemia during second and third trimester of pregnancy. The requirement for formulating standard protocols and guidelines on IV iron use in pregnancy in India was perceived following an observational study conducted across two states of India by MoHFW in collaboration with WHO (145). Intravenous iron supplementation has shown good efficacy and tolerability in the treatment of moderate to severe anemia with good compliance rate in these studies as presented in Table 8. Several RCTs (Table 9) have compared safety and efficacy of IV iron sucrose to IM iron.
Table 8 Summary of studies on intravenous vs oral iron supplementation

<table>
<thead>
<tr>
<th>Author /year</th>
<th>N</th>
<th>Objective</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goginen i S et al, 2015(14 6)</td>
<td>100</td>
<td>IV vs oral: safety &amp; efficacy</td>
<td>IV infusion: IS (200mg; 20–27, 28–32, 33–36 wks)(A)</td>
<td>Oral: (100mg of Ferrous ascorbate OD, 1 hr before food) (B)</td>
<td>↑Hb% (28, 32, 36 &amp; 40 wks). S/E (40 wks), &amp; cost</td>
<td>• Mean diff. in Hb%(A vs B.): 0.3±0.18 vs 0.12±0.88 (p=0.13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• S/E (A vs B): 8% vs 66%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Lost compliance (A vs B): 4% vs40%,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Cost (A vs B): Rs.1600/- vs 1500/-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• IVIS is safe in pregnancy as OI is associated with gastric S/E.</td>
</tr>
<tr>
<td>Sunita VN et al, 2015(14 7)</td>
<td>90</td>
<td>IV vs oral: safety &amp; efficacy</td>
<td>IV infusion: IS (dose as per Hb % &amp; BW: approx. 200-950 mg over 1-8 days)(A)</td>
<td>Target Hb:11g/dL. Target Hb:11g/dL.</td>
<td>↑Hb (A vs B, p=0.0001) (g/dL): 2w-baseline; 1.2±0.05 vs 0.3±0.02, 4w- 2w; 1.01±0.01 vs 0.50±0.001, delv. – 4w; 0.70±0.11 vs 0.50±0.03.</td>
<td>• ↑Hb (A vs B, p=0.0001) (g/dL): 2w-baseline; 1.2±0.05 vs 0.3±0.02, 4w- 2w; 1.01±0.01 vs 0.50±0.001, delv. – 4w; 0.70±0.11 vs 0.50±0.03.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• SF (A vs B) (μg/L): baseline; 11.7±1.47 vs 11.5±1.37 (p=0.5325), 4w; 30.66±4.93 vs 19.96±2.38 (p=0.001), delv; 28.78±5.18 vs 27.32±3.81 (p=0.1624).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Attaining target Hb(A vs B): 57.1%vs 35.1% (p=0.0001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Complications: 3 folds more in group B (p=0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• FBW (A vs B, p=0.72): 2590±508.3 vs 2700±492g.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• The choice of treatment of IDA is OI replacement because it is the safest and least expensive.</td>
</tr>
<tr>
<td>Tembhar</td>
<td>200</td>
<td>IV vs oral: safety &amp; efficacy</td>
<td>IV infusion: IS (dose as per Hb % &amp; BW: approx. 200-950 mg over 1-8 days)(A)</td>
<td>Oral: carbonyl Hb (7)</td>
<td>Mean ↑Hb (A vs B) at 30D: 7.24±1.02 to 9.2±2.04</td>
<td>• Mean ↑Hb (A vs B) at 30D: 7.24±1.02 to 9.2±2.04</td>
</tr>
</tbody>
</table>

**Inclusion criteria**

- Patients with 20-24 wks of gestation
- Patients with 26-32 wks of gestation, Hb(8-10g/dL), SF(<13μg/L)
- Patients with 26-32 wks of gestation, Hb(8-10g/dL), SF(<13μg/L)
<table>
<thead>
<tr>
<th>Study</th>
<th>Methodology</th>
<th>Inclusion Criteria</th>
<th>Efficacy Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>A et al, 2015</td>
<td>Efficacy in IDA: Hb% &amp; BW: 200mg t.i.w. (5mg FA + Albendazole 800mg for 1 wk)</td>
<td>Single pregnancy, &gt;20 wks of gestation, Hb(&lt;10g/dL), SF(&lt;15μg/L)</td>
<td>elemental iron 60mg each 4 wks + 5mg FA + Albendazole 800mg for 1 wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&amp;30D, SF (30D) 10.93±0.92 g/dL vs 7.76±0.45 to 8.85±0.52 g/dL (p&lt;0.0001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Mean rise in SF (A vs B) at 30D: 9.75±2.15 to 53.77±6.53 ng/ml (p&lt;0.0001) vs 10.74±2.00 to 12.70±1.43 ng/ml (p&lt;0.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• IVIS significantly improves the Hb and SF on 30D.</td>
</tr>
<tr>
<td>Tripathi S et al, 2015(149)</td>
<td>IV vs Oral: treatment of IDA</td>
<td>Single pregnancy, gestational age (12-36wks), Hb(6-9g/dL)</td>
<td>Oral: 200mg b.i.d for 6 wks + FA (5mg/day) (B) After 6 wks, Hb, RBC’s indices, SF &amp; TSI. Compliance and S/E</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ↑SF: significant (p&lt;0.001) in group A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ↑TSI (A vs B): 10.1 vs 4.5μg/dL (p&lt;0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ↑Hb (A vs B): 2.3 vs 2.2g/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• RBC’s indices: no diff., S/E (A vs B):6% vs 40%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• IVIS replenishes iron stores much better than OI and had a more favorable improvement in clinical features with fewer S/E, and more effective in later months of pregnancy.</td>
</tr>
<tr>
<td>Abdulla A et al, 2014(150)</td>
<td>IV vs oral: safety &amp; efficacy in moderate anemia</td>
<td>Single pregnancy, moderate anemia (7-10.9g %)</td>
<td>Oral: 100mg elemental iron+ 500μg FA OD (B) After 4 wks, Hb, Hematocrit, MCH, MCHC, MCV, serum iron, TIBC, SF values, S/E &amp; Perinatal outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Hb status (A vs B) (g/dL): initial; 9.3±0.7 vs 9.5±0.6 (p=0.130), follow up; 11.0±0.8 vs 10.8±0.6 (p=0.007)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Hematocrit (A vs B): initial; 28.6±2.7 vs 29.1±1.7(p=0.095)follow up; 33.1±2.4 vs 32.6±4.2 (p=0.704)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• MCH (A vs B): Initial; 26.1±3.2 vs 25.5±3.4 (p=0.222),follow up; 30.0±3.1 vs 30.5±2.7 (p=0.165)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• MCHC (A vs B): Initial; 30.1±3.0 vs 30.6±3.2 (p=0.253),follow up; 34.7±2.9 vs 34.5±3.0 (p=0.615)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• MCV (A vs B): Initial; 79.4±6.4 vs 79.8±6.0 (p=0.638),follow up; 87.0±6.7 vs 87.0±5.6 (p=0.950)</td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Design</td>
<td>Interventions</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>--------</td>
<td>---------------</td>
</tr>
</tbody>
</table>
| **Abhilashini GD et al, 2014** | 100 | IV vs oral: safety & efficacy | IV infusion: IS; (dose as per Hb % & BW: 200mg alt. days; max 600mg/wk.) (A) Target Hb: 11g/dL | • Serum iron (A vs B): Initial; 56.5±7.3 vs 55.5±4.0 (p=0.539), follow up; 73.8±5.1 vs 71.6±4.7 (p=0.121)  
• TIBC (A vs B): Initial; 434.9±69.8 vs 449.6±48.9 (p=0.394), follow up; 345.4±46.0 vs 350.0±51.8 (p=0.741)  
• SF (A vs B): Initial; 11.8±2.0 vs 11.0±1.8 (p=0.153), follow up; 26.2±6.3 vs 16.5±3.7 (p<0.001)  
• S/E & perinatal outcomes: no significant diff. between groups.  
• IVIS is more effective in achieving target Hb & timely use will reduce maternal & fetal complications and risk of transfusion. |
| **Gupta A et al, 2014** | 100 | IV vs oral: safety & efficacy | IV infusion: IS; (dose as Hb % & BW: 200mg alt. days; max 600mg/wk.) (A) Target Hb: 11g/dL | • ↑Hb (A vs B) (g/dL): 2w: 1.266±0.431 vs 1.068±0.447 (p=0.026), 4w: 2.594±0.718 vs 1.992±0.676 (p<0.001), term: 3.954±0.563 vs 2.930±0.565 (p<0.001).  
• ↑% PCV (A vs B): 2w: 4.090±1.985 vs 3.356±1.718 (p=0.051), 4w: 7.938±3.334 vs 6.644±2.300 (p=0.026), term: 11.666±2.470 vs 10.040±1.685 (p<0.001).  
• ↑MCV (A vs B) (fL): 2w: 12.25±6.821 vs 11.02±5.381 (p=0.317).  
• S/E (A vs B): 4% vs 42%  
• IVIS treated IDA faster, effectively than OI without any ADRs. |
<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>IV vs oral:</th>
<th>IV infusion:</th>
<th>Oral:</th>
<th>After 6 wks</th>
<th>S/E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mehta MN et al, 2014(153)</td>
<td>efficacy in treatment of IDA</td>
<td>IS, (dose as Hb % &amp; BW:100mg alt. days). Target Hb:10g/dL</td>
<td>200 mg 2 tablet t.i.d (B)</td>
<td>↑Hb, achieving target Hb</td>
<td>S/E</td>
</tr>
<tr>
<td>Dubey S et al, 2013(154)</td>
<td>response &amp; efficacy</td>
<td>IS, 200mg alt. days (A). Target Hb:11g/dL</td>
<td>↑Hb &amp; SF (2w, 4w &amp; 8w), achieving target Hb</td>
<td>ADR</td>
<td></td>
</tr>
<tr>
<td>Kochhar PK et al, 2013(155)</td>
<td>Efficacy &amp; safety</td>
<td>IS 200mg alt. day (A)</td>
<td>↑Hb (7D, 14D, 21D, 30D &amp; delv.), SF (30D&amp;delv.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Inclusion criteria**
- single pregnancy, 24-34 wks of gestation, Hb(7-9 g/dL), SF(<15μg/L)
- gestational age (<34 wks with IDA(Hb<8g/dL))

**S/E**
- (p<0.001).
  - S/E (A vs B): 10% vs 46%.
  - The ↑Hb is faster with IVIS than OI, which can be beneficial at a later period of gestation and also very well tolerated.

**Mean ↑Hb (A vs B) (g/dL): 3.93±0.60 vs 3.45±0.68 (p=0.284).**
- Target Hb (A vs B): 88% vs 76% patients (p=0.055)
- S/E (A vs B): 35% vs 47%
- IVIS is safe and as effective as OI in the treatment of IDA

**↑Hb: A (5.1 g/dL), B (3.1g/dL), (p=0.002) & SF 30 D (p=0.005)**
- S/E: more in oral group & neonatal outcomes comparable.
- IVIS is a safe for correction of anemia,
<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>IV vs oral: response &amp; efficacy</th>
<th>Inclusion criteria</th>
<th>Oral: 200 mg: b.i.d (4 wks.) + 400mg Albendazole (B)</th>
<th>).S/E</th>
<th>without severe S/E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meenal C et al, 2013(156)</td>
<td>484</td>
<td>IV infusion: IS 200mg: 24 hrs apart) + 400mg Albendazole (A)</td>
<td>Anemic (Hb: 5-10g %) in 2nd/3rd trimesters with no other risk factors</td>
<td>After 4 wks, Hb &amp; ADR</td>
<td>• ↑Hb: in A group, 71.64% patients showed ↑ 2-2.9g/dL, whereas in B group, 77.4% patients showed ↑0.6-0.9g/dL of Hb.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Both group shows minor ADR.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• IVIS can correct anemia in a short period even in advanced pregnancy and prevent associated maternal and perinatal complications.</td>
</tr>
<tr>
<td>Neeru S et al, 2012(157)</td>
<td>100</td>
<td>IV infusion: IS (dose as per Hb %:200mg alt. days) (A)</td>
<td>Target Hb:11g/dL</td>
<td>After 1 month, % Hb, % PCV, % MCV, % MCH, % SF, S/E &amp; compliance, perinatal outcomes</td>
<td></td>
<td>• ↑%Hb (A vs B): 23.62±14.95 vs 14.11±10.66 (p= 0.001).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ↑SF (A vs B): 2032.54±1974.43 vs 180.69±308.39 (p= 0.000).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ↑PCV (A vs B): 20.94±13.55 vs 13.36±12.56 (p= 0.008).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ↑MCV (A vs B): 10.21±9.60 vs 5.47±6.49 (p= 0.008).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ↑MCH (A vs B): 13.46±12.32 vs 7.18±9.68 (p= 0.009).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Compliance (A vs B): 90% vs 88%. S/E (IV vs oral): 13% vs 23%.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Perinatal outcomes: no sign. diff. (p = 0.121–1.000)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• IVIS is safe, effective &amp; stores iron better compared with OI.</td>
</tr>
<tr>
<td>Shafi D et al, 2012(158)</td>
<td>200</td>
<td>IV infusion: IS (dose as per Hb % &amp; BW:200mg alt. days) (A). Target Hb:12g/dL</td>
<td>Patients with 28-37 wks of gestation, Hb(6-10g/dL),</td>
<td>Hb conc. &amp; SF (2, 4 &amp; 6 wks) ADR</td>
<td></td>
<td>• ↑Hb (A vs B) (g/dL) (p=0.000): 2w; 1.72±0.484 vs 0.5750±0.456, 4w; 2.18±0.865 vs 1.39±0.4402, 6w; 2.89±0.599 vs 1.9±0.3020.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ↑SF (A vs B) (ng/ml) (p=0.000**): 2w; 40.020±17.02 vs 8.5±4.5, 4w; 2.612±19.88 vs 15.23±8.09, 6w; 78.53±19.82 vs 26.6±8.56.</td>
</tr>
</tbody>
</table>
**SF(<15μg/L)**

(B)

- S/E (A vs B): 13 vs 22 patients.
- IVIS elevates Hb and restores iron stores faster than OI, with no severe ADRs.

### Prospective studies

| Tandon A et al, 2015 (159) | 400 | IV vs oral: efficacy | IV infusion: 200mg elemental iron diluted in 100ml of 0.9% normal saline, given on alternate days. Total amount was calculated according to iron deficit, based on body weight. | 200 mg FeSO₄ tablets per day for 4 weeks. | Hb, SF, Hematocrit and general blood picture are observed 4 weeks after the last dose was given. | • Baseline and 4 weeks values for various parameters in IV vs oral groups: Hb (gm/dl): 6.17±0.47 & 10.08±0.66 vs 6.92±0.59 & 8.38±1.05 (p=0.004); SF (μg/l): 9.47±1.01 & 285.5±45.1 vs 10.0±1.70 & 162.8±33.1 (p<0.0001); Hematocrit (%): 16.8±1.76 & 46.06±1.99 vs 18.6±1.36 & 33.45±3.17 (p=0.004); MCHC (%): 25.01±1.73 & 34.1±0.97 vs 24.6±2.06 & 32.08±1.41 (p=0.009); MCV (fl): 70.28±0.96 & 93±1.13 vs 70.1±1.96 & 85.8±3.97 (p<0.0001).
- IV therapy is safe, convenient and more effective than oral iron therapy to treat IDA.

### Retrospective studies

| Raut SV et al, 2015 (160) | 200 | IV vs oral: Efficacy in moderate anemia | IV infusion: IS (3 dose of 200mg in alt. days)(A) | Oral: Ferrous ascorbate 100mg elemental iron one tab. OD for 8 wks. | After 8 wks, Hb, Tolerance and S/E | • Mean ↑Hb (A vs B): 1.6g/dL vs 0.87g/dL (p < 0.001).
- S/E (A vs B): 2 vs 42 patients.
- IVIS therapy is much effective in correcting IDA than OI.

| Mani P et al, 2015 (161) | 229 | IV vs oral: Efficacy & tolerance | IVIS infusion (A) Target Hb: 12 g/dL | Oral (B) Hb & SF estimation (2, 4 & 6 wks.) | • A vs B: change in Hb ≥ 1.5g/dL at 4wks, SF raised (p =0.000).
- IVIS in pregnant women was well tolerated.
- IVIS elevates Hb and restores iron faster than OI.
Halimi S et al, 2011 (162)

100 Oral vs IV: safety & efficacy

Ooral: 240mg elemental iron for 4 wks (A)

Inclusion criteria
26-30 wks of gestation, Hb (<11 g/dL), hematocrit (<33 %)

IV infusion
IS (dose as per Hb % & BW) (B)

S/E (15th D)
& Hb (30th D)

- ↑Hb (A vs B) (g/dL) (p=0.0001): 1.85±0.28 vs 3.45±1.06.
- S/E (A vs B): 46% vs 52%.
- IVIS therapy is a better choice to correct IDA.

**, highly significant; BW, body weight; OI, oral iron; SF, serum ferritin; FBW, fetal birth weight; S/E, side effects; IDA, iron deficiency anemia; FA, folic acid; OD, once daily; TSI, total serum iron; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; TIBC, total iron binding capacity; PCV, packed cell volume; ADR, adverse drug reaction; IS, Iron sucrose
Table 9 Summary of studies on intravenous vs intramuscular iron supplementation

<table>
<thead>
<tr>
<th>Author/year</th>
<th>N</th>
<th>Objective</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suguna V et al, 2015 (163)</td>
<td>200</td>
<td>IVIS vs IMIS: Efficacy &amp; safety comparison</td>
<td>IV infusion: 200mg t.i.w. <strong>Inclusion criteria</strong> Patients with Hb(5-9 g/dL), and SF &lt;15 µg/L</td>
<td>IM injection: 2.5ml [150mg] twice monthly.</td>
<td>Hb &amp; RBC indices (2, 4wks &amp; delv.) &amp; SF (delv.) ADR &amp; perinatal outcome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sujatha V et al, 2014 (164)</td>
<td>100</td>
<td>IVIS vs IMIS: safety &amp; efficacy Target Hb (11 g/dL)</td>
<td>IV infusion: (dose as Hb% &amp; BW: 150mg every 3D) <strong>Inclusion criteria</strong> 14-32 wks of gestation with Hb≤8g/dL, se. iron &lt; 60µg/dL &amp; TIBC &gt; 400µg/dL</td>
<td>IM injection: (dose as Hb% &amp; BW: 1.5 ml till cal. dose).</td>
<td>After 4 wks ↑ Hb, time taken for target Hb, ADR</td>
</tr>
<tr>
<td>Singh S et al, 2013 (165)</td>
<td>100</td>
<td>IVIS vs IMIS: safety &amp; efficacy Target Hb (11 g/dL)</td>
<td>IV infusion: (dose as Hb% &amp; BW: 150mg every 3D) <strong>Inclusion criteria</strong> 14-32 wks of gestation with Hb≤8g/dL, se. iron &lt; 60µg/dL &amp; TIBC &gt; 400µg/dL</td>
<td>IM injection: (dose as Hb% &amp; BW: 1.5 ml till cal. dose).</td>
<td>After 4 wks ↑ Hb, time taken for target Hb, ADR</td>
</tr>
<tr>
<td>Dhana ni JV et al, 2012 (166)</td>
<td>60 (52)</td>
<td>IVIS vs IMISCA: safety &amp; efficacy</td>
<td>IV infusion: (dose as Hb% &amp; BW: 200mg alt. days) (Brand: IMAX-S) <strong>Inclusion criteria</strong> Patients with Hb&lt;8.5 g/dL</td>
<td>IM injection: (dose as Hb% &amp; BW: 75mg/D for 4 D) (Brand: JECTOCOS)</td>
<td>↑Hb (14D, 28D), Hemocrit, MCV, MCH, SF (28D). ADR</td>
</tr>
</tbody>
</table>

IVIS, intravenous iron sucrose; S/E, side effects; IMIS, intramuscular iron sorbitol; SF, serum ferritin; FBW, fetal birth weight; ADR, adverse drug reaction; IMISC, intramuscular iron sorbitol citric acid; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; TIBC, total iron binding capacity.
Management of postpartum anemia

Untreated IDA during the postpartum period is a cause of maternal morbidities such as tiredness, lethargy, dizziness, headaches, lactation failure, and postpartum depression (167, 168). Prevalence of postpartum IDA is very high in India (169, 170). The maternal mortality rates are also significant (171). The importance of prevention and treatment of IDA in postpartum period should be given further thrust in the maternal health programs. The WHO guideline recommends postpartum prophylactic iron supplementation of 60 mg elemental iron + 400 µg folic for 3 months (172, 173). Universal iron supplementation was demonstrated to be effective in reducing the prevalence of anemia among low-income postpartum women (174). The MoHFW guideline recommends daily iron (100 mg elemental iron with 500 µg folic acid) for all non-anemic women in postpartum period for 6 months, whereas the same tablet is advised to be taken twice daily for mild to moderately anemic postpartum women (130, 131). Generally anemia in postpartum represents a dire need for iron supplementation, in such anemic patients parenteral iron supplementation was found to be more effective in treating anemia, as compared to oral iron supplementation (159, 175-178).

Among the various preparations of parenteral iron supplementation ferric carboxymaltose was found to be superior to all other parenteral iron supplementation products (179-181). Ferric carboxymaltose (FCM) is a dextran free IV iron preparation that allows rapid administration of high doses of iron (up to 1000 mg iron in 15 min). FCM administration in postpartum has been found to be safe and effective in improving the mean Hb level (181-184). Compared to other parenteral iron preparations FCM has several advantages: It has fewer side effects, single high dose administration is possible and it can reduce the frequency of hospital visits (185).

Postpartum IV iron therapy has been found to avoid demand for blood transfusions (186), and it rapidly replenishes iron stores compared with oral iron (175, 177, 183, 187-192). This is more cost effective option (193). A summary of all postpartum iron intervention studies conducted in India is presented in Table 10.
<table>
<thead>
<tr>
<th>Author /year</th>
<th>N</th>
<th>Objective</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pal SR et al. 2015 (187)</td>
<td>100</td>
<td>IV-IS vs oral Feso4</td>
<td>IV-IS: 200 mg t.i.w (A) <strong>Inclusion criteria</strong> ID with Hb% &lt; 11 g/dL and serum ferritin level ≤ 20 µg/L</td>
<td>Oral Feso4 (B): 60mg b.i.d for 6 weeks</td>
<td>↑ in Hb &amp; ferritin (Day 1, 15, 42)</td>
</tr>
<tr>
<td>Vijayalakshmi S et al. 2015 (188)</td>
<td>120</td>
<td>IV-IS vs oral Feso4</td>
<td>IV-IS: 300-600 mg 2/3 divided doses in alternate day for 3 days (A) <strong>Inclusion criteria</strong> Hb &lt; 10 g/dL within 48 h postpartum</td>
<td>Oral Feso4: 300 mg (100 mg elemental iron) for 28 days (B)</td>
<td>↑ in Hb (g/dL)</td>
</tr>
<tr>
<td>Jain G et al. 2013 (189)</td>
<td>40</td>
<td>IV-IS vs oral Ferrousfumarate</td>
<td>300–600 mg of IV-IS every alternate day for 3 days (A) <strong>Inclusion criteria</strong> Hb &lt; 8 g/dL</td>
<td>Oral: 300 mg ferrous fumarate OD for 14 days (B)</td>
<td>↑ in Hb</td>
</tr>
<tr>
<td>Swati et al. 2013 (190)</td>
<td>50</td>
<td>Oral Feso4 vs IV-IS</td>
<td>Oral Feso4: 200 mg t.i.d for 4 weeks (A)</td>
<td>IV-IS: 100 mg OD for 3 days (B)</td>
<td>Hb, Serum Ferritin</td>
</tr>
<tr>
<td>Rohini et al. 2012 (191)</td>
<td>50</td>
<td>Oral Feso4 vs IV-IS</td>
<td>IV-IS: 200 mg elemental iron for 4 weeks (A)</td>
<td>Oral Feso4: 200 mg tablets t.d.s for 3, Hb ≤ 7 g%</td>
<td>postpartum day 2 or 3, Hb ≤ 7 g%</td>
</tr>
<tr>
<td>Kharde PS et al. 2012 (177)</td>
<td>100</td>
<td>Oral Feso4 vs IV-IS: efficacy in IDA</td>
<td>IV-IS: 200 mg (2^nd &amp; 4^th day) (A) <strong>Inclusion criteria</strong> Hb &lt; 10 g/dL but &gt; 6 g/dL at 24 to 48 hrs post delv. &amp; SF &lt; 15 µg/L.</td>
<td>Oral Feso4: 200 mg b.i.d for 6 wks (B)</td>
<td>Hb, SF (5, 14 &amp; 40D) ADR</td>
</tr>
<tr>
<td>Verma S et al.</td>
<td>150</td>
<td>IV-IS vs oral Feso4:</td>
<td>IV-IS: 600 mg (A) <strong>Inclusion criteria</strong></td>
<td>Oral Feso4: 200 mg b.i.d</td>
<td>Hb (1, 2, 3, 4 wks) &amp; ADR (A vs B)</td>
</tr>
</tbody>
</table>

- **RCT**
- **IV-IS** effective, safe, well tolerated in comparison with OI.
- IV-IS safe, well tolerated, replenishment of both iron stores and Hb.
<table>
<thead>
<tr>
<th>Year (Authors)</th>
<th>Dose</th>
<th>Protocol</th>
<th>Inclusion Criteria</th>
<th>Outcomes</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011 (Garg et al.)</td>
<td>100</td>
<td>IV-FC vs IV-IS</td>
<td>Insevere IDA: efficacy &amp; safety</td>
<td>IV-FC: 1000mg (A) • Inclusion criteria: All normal &amp; cases are del. Patients with IDA. Target Hb = 11 g%</td>
<td>IV-FC: 200mg elemental iron alt. days up to 5D(B) • ↑ in Hb &amp; ADR (2W, 4W, 8W, &amp; 12W)</td>
</tr>
<tr>
<td>2015 (Rathod et al.)</td>
<td>366</td>
<td>IV-FC vs IV-IS vs OI</td>
<td>Safety &amp; efficacy on PPA</td>
<td>IV-FC: 1000mg/wk • Inclusion criteria: Patients with Hb&lt;10 g/dL, with PPA</td>
<td>IV-FC: 300mg alt. day • IV-IS: 100mg OD</td>
</tr>
</tbody>
</table>
| 2015 (Mishra et al.) | 158 | IV-FC: efficacy & safety | | IV-FC: ≤1000mg/wk or 15 mg/kg. • Inclusion criteria: Gestation age >20-36 wks & PP patients with Hb 6-11 g%. | - | • Improvement in Hb: 11.34±0.90, PCV (µg/dL); 402.57±97.28 to 275.59±47.24, SF (ng/ml); 18.30±16.39 to 104.10±32.46, S.Iron (µg/dL) (6w) in OI, IV | • ↑Hb & SF 6 weeks after therapy | • IV-FC should ↓maternal morbidity & mortality. • Mean ↑ in Hb: 3.8 vs. 3.3 g/dL (p = 0.180 for mean difference). • Mean ↑ in SF: 138.70 (p = 0.751 for mean difference). • IV-FC and IV-IS treating mild anemia patients. • % of patients with ↑Hb: Group 1: 98% vs Group 2: 72% (p = 0.004). • % of patients with ↑SF: Group 1: 98% vs Group 2: 72% (p = 0.004). • SF rose significantly in group 2 vs. Group 1: 38.70 (p = 0.751 for mean difference). • FC is an effective protocol. • ↑Hb (g/dL) IV-FC. • Mean ↑ in SF 100% vs 98%.
| 2015 (Hol et al.) | 100 | IV-IS vs IV-FC efficacy & safety in PPA | IV-IS: 500g to mild anemia group (Hb 9-11 g%); 1000g to moderate anemia group (Hb 7-9 g%). • Inclusion criteria: PPA patients with Hb 7-11 g% at 24-48 hrs after delivery. Only IDA patients are considered | IV-IS: 500g and 1000g to mild and moderate anemia groups respectively. • IV-FC: 500g as single dose (Group 2). | - | • Improvement in Hb: 4.58 vs. 4.74 (p = 0.751 for mean difference). Moderate anemia group: 5.94 vs. 6.09 (p = 0.751 for mean difference). • ↑Hb & iron stores (3 wks)Safety. • Achievement of target Hb after 12 wks (A vs B): 100% vs 98%. • FC is an effective therapy. • ↑Hb & SF from baseline | • IV-IS is an effective and faster recovery protocol. • Mean ↑ in Hb: 3.81 vs. 3.3 g/dL (p = 0.180 for mean difference). • Mean ↑ in SF: 138.70 (p = 0.751 for mean difference). • IV-FC should ↓maternal morbidity & mortality. • % of patients with ↑Hb: Group 1: 98% vs Group 2: 72% (p = 0.004). • % of patients with ↑SF: Group 1: 98% vs Group 2: 72% (p = 0.004). • FC is an effective protocol. • ↑Hb (g/dL) IV-FC. • Mean ↑ in SF 100% vs 98%. |
| 2017 (Singh et al.) | 200 | IV-IS vs IV-FC efficacy & safety in PPA | IV-IS: 500g divided in three doses (200g + 200g + 100g) and given on alternate days. (Group 1) • Inclusion criteria: Postpartum patients with Hb ≥7 and <10 gms (10 days post-delivery) and serum ferritin 15 ng/dl (38 weeks of gestation) | IV-FC: 500g as single dose (Group 2). | - | - | • IV-IS is an effective & faster recovery. • Mean ↑ in Hb (g/dL). • Achievement of target Hb 100% vs 98%. • ADR (A vs B): 12% vs 20% (grade 1). • IV-FC is safe, acting better than IV-IS during PP period. |
| 2017 (Joshi et al.) | 200 | IV-FC vs IV-FC | Single dose IV-FC of | IV-IS: | ↑Hb and | • IV-IS is an effective & faster recovery. • Mean ↑ in Hb (g/dL). • Achievement of target Hb 100% vs 98%. • ADR (A vs B): 12% vs 20% (grade 1). • IV-FC is safe, acting better than IV-IS during PP period. |

**Inclusion criteria for various studies:**
- **Postpartum patients with Hb ≥7 and <10 gms (10 days post-delivery) and serum ferritin 15 ng/dl (38 weeks of gestation).**
- **Patients with IDA, Hb <8 g/dL after 24 hr of delv.**
- **Patients with Hb<10 g/dL, with PPA.**
- **Patients with Hb 6-11 g% at 24-48 hrs after delivery. Only IDA patients are considered.**
- **Postpartum patients with Hb 7-11 g% at 24-48 hrs after delivery. Only IDA patients are considered.**
- **Postpartum patients with Hb ≥7 and <10 gms (10 days post-delivery) and serum ferritin 15 ng/dl (38 weeks of gestation).**

**Outcomes for various studies:**
- ** ↑Hb & SF 6 weeks after therapy.**
- ** ↑Hb & iron stores (3 wks)Safety.**
- ** ↑Hb & SF (6w) in OI.**
- ** ↑Hb & SF 6 weeks after therapy.**
- ** ↑Hb & iron stores (3 wks)Safety.**

**Adverse Events for various studies:**
- ** ADR (A vs B): 12% vs 20% (grade 1).**
- ** ADR (A vs B): 12% vs 20% (grade 1).**
- ** ADR (A vs B): 12% vs 20% (grade 1).**
- ** ADR (A vs B): 12% vs 20% (grade 1).**
- ** ADR (A vs B): 12% vs 20% (grade 1).**
**IS efficacy & safety in PPA**

**Inclusion Criteria**

Patients with Hb ≥6 g/dl and ≤11 gm/dl at 10 days post-delivery.

**Inclusion Criteria**

Patients with Hb<10 g%, with PPA

**SF on day 0 and 30 from the last dose of parenteral iron.**

Mean increase (p value 0.000, 0.000)

**↑Hb & SF on 15D (IV vs 4.1 & 4.9 g/L (pregnancy & PP).**

**Mean ↑SF on 15D (IV 9.4 & 8.3 ng/ml (pregnancy & PP).**

**ADR (IV-FC vs IV-FC)**

**↑Hb & stores iron more well tolerated, safe & effective to blood transfusion in the PP period.**

**↑ in Hb & ADR**

**Mean↑Hb on 15D, IV-FC vs IV-FC 4.1 & 4.9 g/L.**

**↑Mean↑SF on 15D, 9.4 & 8.3 ng/ml.**

**↑ADR (IV-FC vs IV-FC).**

**IV-FC↑Hb & stores iron more well tolerated, safe & effective to blood transfusion in the PP period.**

**Blood transfusion**

Severe anemia in last trimester does not permit iron supplementation to completely replenish iron levels, hence, blood transfusion is the treatment of choice for immediate improvement in Hb status (196). The recent Royal College of Obstetricians and Gynaecologists (RCOG) blood transfusion guideline recommends blood transfusion in labor or immediate postpartum.
period if the Hb< 7 g/dL.(197). The indications for blood transfusion are presented in Table 11.

Table 11 Indications of blood transfusion in pregnancy (197, 198, 199)

<table>
<thead>
<tr>
<th>Antepartum Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Pregnancy &lt;34 weeks</td>
</tr>
<tr>
<td>a. Hb &lt;5 g/dL with or without signs of cardiac failure or hypoxia</td>
</tr>
<tr>
<td>b. Hb 5-7 g/dL – in presence of impending heart failure</td>
</tr>
<tr>
<td>2. Pregnancy &gt;34 weeks</td>
</tr>
<tr>
<td>a. Hb &lt;7 g/dL even without signs of cardiac failure or hypoxia</td>
</tr>
<tr>
<td>b. Severe anemia with decompensation</td>
</tr>
<tr>
<td>3. Anemia not due to hematinic deficiency</td>
</tr>
<tr>
<td>a. Hemoglobinopathy or bone marrow failure syndromes</td>
</tr>
<tr>
<td>b. Hematologist should always be consulted</td>
</tr>
<tr>
<td>4. Acute hemorrhage</td>
</tr>
<tr>
<td>a. Always indicated if Hb &lt;6 g/dL</td>
</tr>
<tr>
<td>b. If the patient becomes hemodynamically unstable due to ongoing hemorrhage</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intrapartum Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Hb &lt;7 g/dL (in labor)</td>
</tr>
<tr>
<td>b. Decision of blood transfusion depends on medical history or symptoms</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Postpartum Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Anemia with signs of shock/acute hemorrhage with signs of hemodynamic instability.</td>
</tr>
<tr>
<td>b. Hb &lt;7g% (postpartum): Decision of blood transfusion depends on medical history or symptoms</td>
</tr>
</tbody>
</table>

Deworming

The prevalence data on soil-transmitted helminthiasis is not uniformly available in India, but clinical experience shows the high burden of worm infestation in the community. Intestinal helminthiasis and Hb concentrations are known to have an inverse relationship (200); hence, administration of anthelmintic agents has been recommended as an additional intervention to reduce anemia. A systematic review of RCTs evaluating the effect of anthelmintic drugs on Hb demonstrated mean Hb increase of 1.71 g/dL (201).

A recent Cochrane review found insufficient evidence to recommend deworming in pregnancy (202), though there is a demonstrable benefit of deworming in endemic areas (203). In hookworm-endemic areas, WHO risk–benefit analysis confirmed the benefits of deworming in endemic areas – this is evidenced by improved infant birth weight and survival (204) and reduced maternal anemia (205). For soil-transmitted helminthiasis, WHO recommend offering albendazole or mebendazole to pregnant women in the second
and third trimesters of pregnancy and to lactating women as a preventive therapeutic interventions in areas where the prevalence of any soil-transmitted helminth infection (hookworm infection, ascariasis, and trichuriasis) exceeds 20% (206). The national guidelines for deworming in pregnancy by the MoHFW, Government of India, recommend a single dose of 400 mg of albendazole tablet after the first trimester, preferably in the second trimester (207).

**Malaria**

According to the WHO global estimates, there are about 207 million cases of malaria, and 6,27,000 deaths attributable to malaria in 2012 (208). The report finds approximately 80% of these cases in African countries and 13% in South East Asia Region (SEAR) countries (208), of this, India contributes to 61% of malaria cases and 41% deaths due to malaria (209). The reported prevalence of malaria in pregnancy varies from 46-51% in India (210-214). Malaria increases the risk of maternal anemia, placental parasitaemia, stillbirth, spontaneous abortion, LBW and neonatal deaths (131, 215,).

The WHO recommends a three-pronged approach to the prevention and management of malaria during pregnancy, which includes: insecticide-treated nets (ITNs), intermittent preventive treatment (IPT), and effective care management of malarial illness (216). The IPT with at least 2 doses of sulphadoxine pyrimethamine (SP) has been found to reduce the prevalence of maternal anemia and placental parasitemia; and the incidence of LBW in the second and third trimesters of pregnancy in several studies conducted in Africa (217-220-). Furthermore, use of a combination of SP and INTs during second and third trimester can result in better control of malaria in the high prevalence area (221). However, we could not find the evidence on IPT in India. The 2013 guideline on diagnosis and treatment of malaria in India recommends chloroquine for the treatment of *Plasmodium vivax* during pregnancy. Quinine is recommended for *Plasmodium falciparum* malaria during the first trimester and artemisinin combination therapy in the second and third trimesters of pregnancy (222).

**Co-supplementation with other micronutrients**

Folic acid or folate insufficiency during pregnancy is directly associated with adverse pregnancy complications and poor birth outcomes. These includes the risk of preterm birth, LBW, intrauterine growth restriction (IUGR) and neural tube defect (NTD) in the neonates (223). Folate supplementation and fortified food can reduce the incidence of NTD by 46%
and neonatal death by 13% (224). Therefore, the addition of 500µg of folic acid or folate during antenatal period is necessary to avoid the maternal and perinatal complications.

Maternal Vitamin B₁₂ deficiency is directly associated with adverse pregnancy complications and poor birth outcomes, e.g. LBW (225), IUGR (226), & NTD (227). A 2.6 µg & 2.8 µg of Vitamin B₁₂ daily during pregnancy and lactation, respectively, need to be added to avoid the maternal and neonatal complications (228).

When taken along with the iron rich foods, Vitamin C increases the iron absorption, especially the non-heme iron (49). One study in India reveals that the addition of Vitamin C in the lunch increases the Hb level and supports in reducing the IDA (229). However, the recommended dietary allowance (RDA) of Vitamin C is sufficient enough to bring this action so an extra amount of supplement may be undesirable (68). Moreover, recent Cochrane data do not support preventive Vitamin C supplementation alone or in combination with other supplements to reduce poor fetal growth, fetal or neonatal death, pre-eclampsia, and preterm birth (230). Vitamin C usage other than enhancing the absorption of iron, its routine supplementation in IDA is not advised.

A systemic review of 13 RCTs shows no advantage in reducing maternal mortality with vit-A compared with placebo or when added to iron supplements (231). A prophylactic vit-A supplementation to prevent maternal and infant morbidity and mortality is not recommended (232).
**Appendix I. Iron rich food, iron (mg/100g)(233)**

<table>
<thead>
<tr>
<th>Section</th>
<th>Foods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Cereal grains and products</strong></td>
<td>Whole wheat flour (4.9), Ragi (3.9), Jowar (4.1), Samai (9.3)</td>
</tr>
<tr>
<td><strong>2. Pulses and legumes</strong></td>
<td>Bengal gram roasted (9.5), Bengal gram dhal (5.3), Cow pea (8.6), Green gram, whole (4.4), Horse gram, whole (6.77), Lentil (7.58), Dry peas (7.05), Soya bean (10.4)</td>
</tr>
<tr>
<td><strong>3. Leafy vegetables</strong></td>
<td>Amaranth polygonoides (Ramdana or Rajgeera)(27.3), Amaranth tristis (38.5), Beet greens (16.2), Bengal gram leaves (23.8), Cauliflower greens (40.0), Mustard leaves (16.3), Radish leaves (18.0)</td>
</tr>
<tr>
<td><strong>4. Roots and tubers</strong></td>
<td>Beet root (1.19), Carrot (1.03), Mango ginger (2.6), Onion small (1.2), Potato (0.48), Radish table (1.0)</td>
</tr>
<tr>
<td><strong>5. Other vegetables</strong></td>
<td>Beans (2.6), Cowpea pods (2.5), Onion stalks (7.43)</td>
</tr>
<tr>
<td><strong>6. Nuts and oil seeds</strong></td>
<td>Almond (5.09), Cashewnuts (5.81), Coconut dry (7.8), Garden cress seeds (100), Gingelly seeds (9.3), Groundnut (2.5), Niger seeds (56.7)</td>
</tr>
<tr>
<td><strong>7. Fruits</strong></td>
<td>Ambada (3.9), Apricot dry (4.6), Currants, black (8.5), Dates dried (7.3), Watermelon (7.9), Peaches (2.4), Pineapple (2.42), Seethaphal (4.31)</td>
</tr>
<tr>
<td><strong>8. Meat and poultry</strong></td>
<td>Beef meal (18.8), Egg, hen (2.1), Liver, sheep (6.3), Mutton, muscle (2.5)</td>
</tr>
<tr>
<td><strong>9. Milk and milk products</strong></td>
<td>Cheese (2.1), khoa (5.8)</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>DALYs</td>
<td>disability-adjusted life in years</td>
</tr>
<tr>
<td>DFS</td>
<td>double fortified salt</td>
</tr>
<tr>
<td>EPP</td>
<td>erythrocyte protoporphyrin</td>
</tr>
<tr>
<td>FOGSI</td>
<td>Federation of Obstetric and Gynecological Societies of India</td>
</tr>
<tr>
<td>GCPR</td>
<td>Good Clinical Practice Recommendations</td>
</tr>
<tr>
<td>GDP</td>
<td>gross domestic product</td>
</tr>
<tr>
<td>GI</td>
<td>gastro intestinal</td>
</tr>
<tr>
<td>Hb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>ID</td>
<td>iron deficiency</td>
</tr>
<tr>
<td>IDA</td>
<td>iron deficiency anemia</td>
</tr>
<tr>
<td>IFA</td>
<td>iron and folic acid</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IPT</td>
<td>intermittent preventive treatment</td>
</tr>
<tr>
<td>ITNs</td>
<td>insecticide-treated nets</td>
</tr>
<tr>
<td>IUGR</td>
<td>intrauterine growth restriction</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>LBW</td>
<td>low birth weight</td>
</tr>
<tr>
<td>MCH</td>
<td>mean corpuscular hemoglobin</td>
</tr>
<tr>
<td>MCHC</td>
<td>mean cell hemoglobin concentration</td>
</tr>
<tr>
<td>MCV</td>
<td>mean corpuscular volume</td>
</tr>
<tr>
<td>MoHFW</td>
<td>Ministry of Health and Family Welfare</td>
</tr>
<tr>
<td>NaFeEDTA</td>
<td>sodium iron ethylene diamine tetra acetic acid</td>
</tr>
<tr>
<td>NE</td>
<td>nutrition education</td>
</tr>
<tr>
<td>NFHS</td>
<td>National Family Health Survey</td>
</tr>
<tr>
<td>NTD</td>
<td>neural tube defect</td>
</tr>
<tr>
<td>PGART</td>
<td>patient global assessment of response to therapy</td>
</tr>
<tr>
<td>PGATT</td>
<td>patient global assessment of tolerability to therapy</td>
</tr>
<tr>
<td>RBCs</td>
<td>red blood cells</td>
</tr>
<tr>
<td>RCOG</td>
<td>Royal College of Obstetricians and Gynaecologists</td>
</tr>
<tr>
<td>RCTs</td>
<td>randomized clinical trials</td>
</tr>
<tr>
<td>RDA</td>
<td>recommended dietary allowance</td>
</tr>
<tr>
<td>RDW</td>
<td>red cell distribution width</td>
</tr>
<tr>
<td>SEAR</td>
<td>South East Asia Region</td>
</tr>
<tr>
<td>SP</td>
<td>sulphadoxine pyrimethamine</td>
</tr>
<tr>
<td>sTfR</td>
<td>soluble serum transferrin receptor</td>
</tr>
<tr>
<td>sTfR-F</td>
<td>soluble transferrin receptor-log [ferritin]</td>
</tr>
<tr>
<td>TIBC</td>
<td>total iron binding capacity</td>
</tr>
<tr>
<td>WHO</td>
<td>World health organization</td>
</tr>
<tr>
<td>ZPP</td>
<td>zinc protoporphyrin</td>
</tr>
</tbody>
</table>
References


135. Agency EM. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. 2013


172. WHO. Recommendations on Postnatal Care of the Mother and Newborn. 2013.


178. Chaurasia A, Singh N, Gupta V, Beenu. A prospective study comparing the efficacy of oral iron, intra-venous Ironsucrose and Ferric-carboxy-maltose in


212. Sohail M, Shakeel S, Kumari S, et al. Prevalence of Malaria Infection and Risk Factors Associated with Anaemia among Pregnant Women in Semiurban...


222. Guidelines for Diagnosis and Treatment of Malaria in India. New Delhi: National Institute of Malaria Research; 2014.


229. Gopaldas T. Iron-deficiency anemia in young working women can be reduced by increasing the consumption of cereal-based fermented foods or gooseberry juice at the workplace. Food Nutr Bull. 2002;23:94-105.


